These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 2465966)

  • 21. In vitro stability studies of a Factor IX concentrate (Bebulin).
    Dal Bo Zanon R; Gazzetta R; Patrassi G; Stocco D; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(6):874-8. PubMed ID: 6200399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
    Teh LC; Woodfield DG
    Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fractionation of cold-sterilized plasma. A new concept in production of non-infectious plasma proteins.
    Stephan W
    Arzneimittelforschung; 1982; 32(8):799-801. PubMed ID: 6890353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arrhenius relationships from the molecule and cell to the clinic.
    Dewey WC
    Int J Hyperthermia; 2009 Feb; 25(1):3-20. PubMed ID: 19219695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The stability of factor IX concentrate during storage.
    Suomela H; Vahtera E
    Thromb Haemost; 1982 Apr; 47(2):114-5. PubMed ID: 7101229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.
    Roberts PL; Hart H
    Biologicals; 2000 Sep; 28(3):185-8. PubMed ID: 10964445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [No ELISA detectable alterations in immunogenicity following dry-hear treatment (72 hours at 80 degrees C) of FANHDI].
    Bravo MI; Massot M; Jorquera JI
    Sangre (Barc); 1999 Dec; 44(6):412-7. PubMed ID: 10822752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of plasma collection systems and processing parameters on the quality of factor IX concentrate.
    Farrugia A; Spiers D; Young I; Oates A; Herrington R; Damianos F
    Vox Sang; 1989; 57(1):4-9. PubMed ID: 2800464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro characterization of various factor VIII concentrates.
    Yoshioka A; Shima M; Nishino M; Yoshikawa N; Fukui H
    Arzneimittelforschung; 1987 Jul; 37(7):753-6. PubMed ID: 3118888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography.
    Feldman PA; Bradbury PI; Williams JD; Sims GE; McPhee JW; Pinnell MA; Harris L; Crombie GI; Evans DR
    Blood Coagul Fibrinolysis; 1994 Dec; 5(6):939-48. PubMed ID: 7893930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
    Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
    Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of monosaccharides during severe dry heat treatment of coagulation factor VIII concentrates.
    Knevelman A; de Wit HJ; Griffin B; Hart H; McIntosh RV
    Vox Sang; 1994; 66(2):96-103. PubMed ID: 8184599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation of factor IX concentrate from platelet-rich plasma.
    Smith JK; Snape TJ; Bidwell E
    Thromb Haemost; 1977 Apr; 37(2):363-6. PubMed ID: 577635
    [No Abstract]   [Full Text] [Related]  

  • 38. Application of semi-industrial monolithic columns for downstream processing of clotting factor IX.
    Branović K; Buchacher A; Barut M; Strancar A; Josic D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jun; 790(1-2):175-82. PubMed ID: 12767330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis A transmission by factor IX concentrates: control by severe dry heat treatment at 80 degrees C.
    Roberts P; Feldman P
    Vox Sang; 1997; 73(3):189-90. PubMed ID: 9358623
    [No Abstract]   [Full Text] [Related]  

  • 40. Production of highly purified clotting factor IX by a combination of different chromatographic methods.
    Hoffer L; Schwinn H; Josić D
    J Chromatogr A; 1999 Jun; 844(1-2):119-28. PubMed ID: 10399328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.